JP2016539911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539911A5 JP2016539911A5 JP2016517288A JP2016517288A JP2016539911A5 JP 2016539911 A5 JP2016539911 A5 JP 2016539911A5 JP 2016517288 A JP2016517288 A JP 2016517288A JP 2016517288 A JP2016517288 A JP 2016517288A JP 2016539911 A5 JP2016539911 A5 JP 2016539911A5
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- peptide
- peptide according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 14
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 238000001784 detoxification Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000008034 disappearance Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002703 mutagenesis Methods 0.000 claims description 2
- 231100000350 mutagenesis Toxicity 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102013016002.2A DE102013016002A1 (de) | 2013-09-26 | 2013-09-26 | Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung |
| DE102013016002.2 | 2013-09-26 | ||
| DE102014003262.0A DE102014003262A1 (de) | 2014-03-12 | 2014-03-12 | Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz |
| DE102014003262.0 | 2014-03-12 | ||
| PCT/DE2014/000477 WO2015043567A1 (de) | 2013-09-26 | 2014-09-23 | Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539911A JP2016539911A (ja) | 2016-12-22 |
| JP2016539911A5 true JP2016539911A5 (https=) | 2018-12-27 |
| JP6660877B2 JP6660877B2 (ja) | 2020-03-11 |
Family
ID=51932152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517288A Active JP6660877B2 (ja) | 2013-09-26 | 2014-09-23 | アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10995118B2 (https=) |
| EP (2) | EP3747454B9 (https=) |
| JP (1) | JP6660877B2 (https=) |
| CN (1) | CN105745219B (https=) |
| DK (1) | DK3049099T3 (https=) |
| ES (2) | ES2818929T3 (https=) |
| WO (1) | WO2015043567A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016125645A1 (de) * | 2016-12-23 | 2018-06-28 | Forschungszentrum Jülich GmbH | D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz |
| CN106866792B (zh) * | 2017-02-24 | 2020-09-04 | 中山大学 | 一类环十肽分子及其应用 |
| DE102017010842A1 (de) * | 2017-11-23 | 2019-05-23 | Forschungszentrum Jülich GmbH | Verfahren zur Quantifizierung von Proteinaggregaten einer Proteinfehlfaltungserkrankung in einer Probe |
| DE102021121435A1 (de) | 2021-08-18 | 2023-02-23 | Priavoid Gmbh | Aß-BINDENDE SUBSTANZEN |
| WO2025038979A1 (en) * | 2023-08-16 | 2025-02-20 | LVIS-Regain LP | Compositions and methods for prophylaxis and/or treatment of amyloid b peptide proteinopenia in alzheimer's and other diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US7384910B2 (en) * | 1997-10-08 | 2008-06-10 | Castillo Gerardo M | Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| EP1141250B1 (en) | 1998-12-18 | 2006-03-01 | The Penn State Research Foundation | Intein-mediated cyclization of peptides |
| AU781044B2 (en) | 1999-11-05 | 2005-05-05 | Axonyx, Inc. | Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof |
| WO2001036431A1 (en) | 1999-11-15 | 2001-05-25 | Parker Hughes Institute | Diamino platinum (ii) antitumor complexes |
| DE10117281A1 (de) | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| US20070021345A1 (en) * | 2003-06-30 | 2007-01-25 | Ehud Gazit | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| GB0503434D0 (en) | 2005-02-18 | 2005-03-30 | Senexis Ltd | Amyloid-binding peptides, analogues and uses thereof |
| DE102005049537B4 (de) | 2005-10-17 | 2010-04-22 | Forschungszentrum Karlsruhe Gmbh | Verfahren zur Herstellung zyklischer Peptide und Verwendung der derart hergestellten zyklischen Peptide |
| DE102006015140A1 (de) | 2006-03-31 | 2007-10-11 | Philipps-Universität Marburg | Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen |
| WO2007145589A1 (en) * | 2006-06-15 | 2007-12-21 | Per Arvidsson | Peptides that are capable of binding to amyloid-beta peptide. |
| JP2010521526A (ja) | 2007-03-23 | 2010-06-24 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | 多価ヘテロ二官能性ポリマーおよびその使用方法 |
| DE102008037564A1 (de) * | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
| DE102010019336A1 (de) | 2010-05-05 | 2011-11-10 | Forschungszentrum Jülich GmbH | Mittel zur Behandlung der Alzheimerschen Demenz |
| DE102010017130B4 (de) | 2010-05-28 | 2018-11-29 | Forschungszentrum Jülich GmbH | Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung |
| WO2013021353A1 (en) | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| DE102012102998B4 (de) | 2012-04-05 | 2013-12-05 | Forschungszentrum Jülich GmbH | Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung |
| DE102012102999A1 (de) | 2012-04-05 | 2013-10-10 | Forschungszentrum Jülich GmbH | Verfahren zur Behandlung von Blut, Blutprodukten und Organen |
| EP2834644B1 (de) | 2012-04-05 | 2019-08-21 | Forschungszentrum Jülich GmbH | Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung |
| DK2834643T3 (da) | 2012-04-05 | 2020-02-03 | Forschungszentrum Juelich Gmbh | Fremgangsmåde til behandling af blod, blodprodukter og organer |
| US10030056B2 (en) | 2013-04-30 | 2018-07-24 | Forschungszentrum Juelich Gmbh | Agents for preventing and treating HIV and other viral infections |
-
2014
- 2014-09-23 EP EP20180219.6A patent/EP3747454B9/de active Active
- 2014-09-23 CN CN201480053169.1A patent/CN105745219B/zh active Active
- 2014-09-23 JP JP2016517288A patent/JP6660877B2/ja active Active
- 2014-09-23 US US15/022,749 patent/US10995118B2/en active Active
- 2014-09-23 WO PCT/DE2014/000477 patent/WO2015043567A1/de not_active Ceased
- 2014-09-23 ES ES14799955T patent/ES2818929T3/es active Active
- 2014-09-23 ES ES20180219T patent/ES2953883T3/es active Active
- 2014-09-23 EP EP14799955.1A patent/EP3049099B1/de active Active
- 2014-09-23 DK DK14799955.1T patent/DK3049099T3/da active
-
2020
- 2020-06-22 US US16/908,606 patent/US11274125B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539911A5 (https=) | ||
| MX2011010353A (es) | Composicion farmaceutica. | |
| JP2017158561A5 (https=) | ||
| JP2017501130A5 (https=) | ||
| CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
| MY207132A (en) | Anti-tau antibody and use thereof | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2019513752A5 (https=) | ||
| JOP20220316A1 (ar) | لقاح متعدد الحاتمات لمعالجة مرض الزهايمر | |
| EA201000809A1 (ru) | АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА | |
| JP2006506942A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| JP2018516944A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| MX2023003009A (es) | Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. | |
| JPWO2020059847A5 (https=) | ||
| JP2015531348A5 (https=) | ||
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| MX2023001501A (es) | Vacuna tau para tratamiento de enfermedad de alzheimer. | |
| WO2006087550A3 (en) | Amyloid-binding peptides, analogues and uses thereof | |
| CN103339142B (zh) | 能够穿过血脑屏障的药物递送材料，和肽及其应用 | |
| CN105745219B (zh) | 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途 | |
| CN107428811B (zh) | 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A-β-物类的肽 | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten |